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Introduction
Hepatitis B virus (HBV) is known as a small enveloped 
virus with a partially double-stranded 3.2 kb DNA genome 
belonging to the Hepadnaviridae family (1). HBV infection 
is also considered as one of the main causes of chronic 
hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) (2). 
Approximately 350 million people across the world are 
estimated to be persistent carriers of HBV and most of 
them may have a chronic hepatic disease (3). Recently, 
microRNA (abbreviated as miRNA) family has been taken 
into consideration in virology research. It should be noted 
that miRNAs are conserved in their evolutions; in this 
regard, small RNAs (18–25 ribonucleotide) are non-coding 
and they are able to regulate numerous biological processes 
such as cellular evolution, differentiation, proliferation, 
apoptosis, as well as metabolism (4). Moreover, they can play 
a significant role in pathogenesis of chronic inflammation 
and cancer (5,6). Various cellular changes can be also 
mediated by miRNA expression indicating that miRNA 
expression is able to improve pathogenesis understanding 
of HBV and make new methods for HBV treatment. 
Besides, miRNA molecules are used as a prognostic and 
diagnostic factor for disease assessment. Recent studies in 
this domain have suggested that miRNAs are manifold in 
the liver and they can regulate a wide range of its functions. 
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Some of the miRNAs found in serums and tissues can 
similarly have a role in diagnosis of HBV infection-related 
tumors (7,8). MiRNA dysregulation is likely to occur in 
all the stages of hepatocarcinogenesis. Moreover, miRNA 
profiles can differentiate between healthy people and those 
affected with HCC (9,10). Such profiles are also different 
in benign and malignant tissues and they may be different 
in terms of malignancy by their sub-type (11). MiRNAs 
can be diagnosed in hepatic tumors, serums, plasmas, and 
urines which can be considered as a non-invasive method 
for evaluating responses towards treatments and a kind 
of prognosis in this disease. As well, etiology-related 
differences in miRNA expression may complicate efforts 
to develop effective biomarker panels due to geographic 
differences in the underlying causes of HCC. Pathogeneses 
of diseases related to HBV are unknown and treatment 
strategies in this regard are not sufficient. Multiple studies 
have indicated that HBV infection can change cellular 
expressions of miRNAs. Moreover, various miRNAs are 
able to express themselves in different stages of HBV; for 
example, some miRNAs can have a significant role in early 
hepatic tumors and metastasis. Recently, some reports 
have revealed that miRNAs can be utilized as a marker for 
hepatic diseases and HBV infections (12-15). The selected 
and valid miRNA markers are also applied on a wide range 
of serums and plasmas of HBV-infected patients along with 
healthy individuals. A combination of these experimental 
results has been also applied on rat models with a hepatic 
disease. The results of this application have suggested 
that plasma concentration changes of miRNA-122 could 
be dependent on severity of the disease in rat and human 
models. The changes in miRNA-122 can occur earlier 
than those of aminotransferase activities. The related 
studies have similarly indicated that miRNA-122 can have 
a potential to be used as a blood marker in hepatic diseases 
such as HBV (14). In this regard, Waidmann et al. analyzed 
the relationship between miRNA-122 and HBV infection. 
They showed that a serum level of miRNA-122 was able 
to differentiate between healthy people and HBV-infected 
ones (12,13). Some of the circulating miRNA changes 
also happened due to the severity of HBV symptoms and 
miRNA-122 expression in these patients could be reported 
significantly higher than that in healthy individuals (15). 
Since miRNA-122 has a high expression in the liver and 
tumor suppressor-like qualities, researchers are interested 
to know whether miRNA-122 expression can change under 
HBV hepatic disease in serums on not. MiRNA-122 is 
located in the intragenic region of 18q21.31 (16). According 
to the significant role of miRNA-122 in liver physiology, its 
expression can be suppressed by HBV, which may prevent 
hepatic disorders and control hepatic diseases such as HCC. 
Since miRNA-122 has a central role in liver disease and 
biology, it can be a significant treatment target for hepatic 
diseases such as hepatitis, fibrosis, steatosis (fatty change), 
and HCC. Furthermore, studies conducted in this domain 
have reported that miRNA-122 suppression can be an 
efficient method for decreasing viral loads in HBV patients. 
The research on miRNA-122 has also continued as a 
treatment and a diagnosis target for HBV infection.
MiRNA-122 is the most abundant among exclusive 
hepatic miRNAs and it makes 70% of all the colonized 
miRNAs from the liver (17). In this respect, studies 
have indicated that miRNA-122 can have a key role in 
controlling the growth of hepatocytes and neoplastic 
transformations (18). It can also play a significant role in 
regulating metabolisms, lipids, hepatic cirrhosis, and HBV 
replication changes (19-21). Such studies have similarly 
showed that miRNA-122 can have a suppression effect 
on HBV replication. Moreover, interaction between 
miRNA-122 expression levels and replication of HBV has 
demonstrated the suppression effects of miRNA-122 on 
HBV via base-pairing of HBV sequences (22,23). In this 
respect, miRNA-122 can control HBV through down-
regulating Cyclin G1 and increasing p53 activities (23). 
The serum miRNA-122 levels can be also correlated with 
the serum levels of ALT, HBV DNA, and HBsAg in clinical 
settings (13,24). Therefore, patients with high levels of 
HBsAg can be exposed to viral flare-up; moreover, their 
serum miRNA-122 level can be reported high. According 
to the fact that miRNA-122 is able to increase the quickness 
of hepatitis C virus (HCV) replication and suppress HBV 
one, the potentials of miRNA-122 in patients infected 
with HBV and HCV is an interesting issue for clinical 
analyses. In cultured cells, HBV infection is likely to 
decrease or increase the expression of miRNA-122 leading 
to lower HBV replication (22). Furthermore, an inverse 
linear relationship can be observed between miRNA-122 
levels and viral loads in peripheral-blood mononuclear 
cells of HBV patients (22). In this line, research studies 
have reported that HBV infection can increase the level 
of pri-miRNA-122, but decrease the level of miRNA-122 
since HBV sequences can have several binding sites for 
miRNA-122 (25). The reason for the high serum levels of 
miRNA-122 in patients with high HBsAg has not become 
clear yet. However, one of the potential reasons is that 
intracellular miRNA-122 is carried out into the serum by 
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virus or host proteins. Therefore, miRNA-122 level can 
increase in the serum. Argonaut 2 and HBsAg have been 
also proved to have the ability of carrying miRNAs—such 
as miRNA-122—into the blood circulation (15,26). Besides, 
the increase of miRNA-122 in serum can be created by 
released miRNA-122 from the damaged hepatocytes caused 
by inflammation (14). Anti-tumor functions of miRNA-122 
in the liver can be also analyzed using miRNA-122 KO mice 
(27,28). These rat models can spontaneously progress liver 
tumors and show abnormal expression of genes involved 
in cell growth, cell death, and epithelial-mesenchymal 
transition (EMT) (27,28). Tumor progression in these 
mice can be also reduced as the expression of miRNA-122 
increases (27,28). Furthermore, using a mouse model where 
tumors are developed despite the absence of inflammation, 
it has been revealed that miRNA-122 can have an anti-
tumor function independent of its role in inhibiting liver 
disease and inflammation (27).
MiRNA-122 and hepatitis B-associated HCC 
MiRNA-122 can have a significant role in EMT of 
hepatic cells and HCC progression (28,29). The level 
of miRNA-122 is down in HCC, and the low level of 
miRNA-122 can be a poor prognosis in this type of 
cancer (30,31). In an in vivo experiment, overexpression of 
miRNA-122 could reduce tumorigenic properties of HCC 
cells indicating the fact that miRNA-122 could be assumed 
as a tumor suppressor (32). Furthermore, hydrodynamic 
injection of miRNA-122 into 3-month old miRNA-122-
deficient mice with problems in miRNA-122 expression 
could bring about a disorder in tumor progression and, 
eventually, cause a decrease in size and occurrence of 
the tumor (28). Intra-tumor injection of miRNA-122 
encapsulated in nanoparticles of cationic lipid could also 
reduce the growth of HCC Xenograft up to 50% and 
consequently suppress the targeted genes along with 
angiogenesis. Increasing the characteristics of miRNA-122 
expression on the tumor, could reverse the hepatoma 
and prevent the formation of HCC in vivo conditions 
(27,28,32-36). According to this issue, the potential future 
strategies for therapies by restoring the expression of 
miRNA-122 in order to prevent or treat HCC in patients 
with low levels of miRNA-122 can be appropriate ones 
for HCC. Thus, miRNA-122 can be a potentially suitable 
treatment for HCC. In fact, since the reduction of 
miRNA-122 can cause hepatocarcinogenesis, increasing 
the expression of miRNA-122 in HCC cells is able to 
change tumor characteristics of these cells and prevent the 
progression of HCC in vivo (27,28). It should be noted 
that miRNA-122 expression in human HCC is low. The 
increase of miRNA-122 expression can also prevent HCC 
growth; furthermore, it can promote cellular apoptosis by 
affecting the signaling path of WNT/b-Catenin-TCF (37) 
which has a binding site for miRNA-122 and can function 
as a sponge for it (25). Moreover, a recent study indicated 
that HBx protein could be a binding to PPARC and 
inhibit the transcription of miRNA-122 (38). It was also 
able to decrease miRNA-122 stability via reducing the 
amount of Gld2 production, which can be of significance 
in miRNA-122 adenylation (39). It has been reported that 
the HBV-mediated downregulation of miRNA-122 can 
also increase the expression of the tumor promoter N-myc 
downstream regulated gene 3 (NDRG3) (40) which can 
further enhance the expression of the miRNA-122 target 
Cyclin G1 (CCNG1) and result in improved Akt activation 
leading to EMT (41). MiRNA-122 inhibition by HBV can 
also increase PTTG1 which can affect the growth of the 
tumor and cell invasion (25). Besides, these HBV changes in 
regulatory networks can cause the progression of HCC.
Role of miRNA-122 in molecular pathogenesis  
of HBV
Some types of proteins targeted by miRNA-122 have been 
identified. The signaling path of WNT/b-catenin is also 
active in 30% of HCCs (42,43) which are directly targeted 
by miRNA-122 (37,44). The decrease of WNT1 by 
miRNA-122 can also lead to a down-regulation of b-catenin 
expression and reduction of the WNT/b-catenin signaling 
(37,44). RhoA, a Ras homolog gene family member, can 
be a potential target of miRNA-122. MiRNA-122 may 
directly block the EMT by inhibiting RhoA. It can also 
target insulin growth factor (IGF)-1R, and consequently, 
reduce IGF-1R/AKT signaling. This process can reduce 
the activity of glycogen synthase kinase-3b (GSK-3b) and 
cellular growth (45,46). MiRNA-122 can also inhibit HBV 
replication by modulating the expression of type-I interferon 
(IFN), which can have a significant role in host antiviral 
responses, such as protection from HBV infection (47). 
The activity of JAK/STAT signaling path can be negatively 
regulated by SOCS. MiRNA-122 can also down-regulate 
SOCS3. An increase of SOCS3 expression in chronic 
hepatitis B (CHB) patients is likely to produce inefficient 
immunity, which causes viral persistence (48). Moreover, 
the hepatic SOCS3 level can be higher in CHB patients, 
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especially in those individuals who do not respond to 
IFN treatments (49-52). The decrease of miRNA-122 
expression in HBV can similarly increase the expression of 
cyclin G1 gene. Then, cyclin G1 can attenuate the activity 
of P53, which increases HBV replication. Therefore, loss 
of miRNA-122 expression in HBV patients may activate 
modulating cyclin G1 and increase HBV replication (23,25). 
HBx-LINE1 is a combination of human LINE1 and HBx 
gene of HBV. In HCC tumor cells, HBx-LINE1 can act 
as a sponge for miRNA-122 and remove it from the cell. It 
also activates B-Catenin signaling of hepatic cells, reduces 
E-cadherin, increases cell migration, and produces an 
abnormal mitosis and hepatic damage in rats (53).
Polymorphisms miRNA-122 in HBV
The 5'UTR of the target mRNAs can have a significant 
role in inflammatory diseases caused by HBV and 
hepatocarcinogenesis (54,55). Polymorphism in the binding 
site of miRNA to mRNA can also change the binding power 
of miRNA and regulate target genes; therefore, it can affect 
patients’ sensitivity to cancer (56). In a study, it was reported 
that polymorphism in the binding site of miRNA-122 in 
IL-1A gene could have a risk of HCC (57). The variant 
allele of rs3783553 could also significantly decrease the 
cancer-promoting effect of HBV preS deletion in the 
HBV-infected subjects. These results could contribute 
to understanding the complex viral metabolism in HCC 
progression, and diagnosing HBV patients predisposed to 
HCC (58). Rs4309483 polymorphism can also affect the 
expression of miRNA-122 and create a protection against 
CHB infection. However, it increases the risk of HCC 
in HBV carriers (59). Moreover, the basic expression of 
miRNA-122 can be highly influenced by rs2999200 and 
rs6551952 single nucleotide polymorphism (60).
MiRNA-122 and chemotherapy
Recently, the first miRNA mimic reached phase-one 
clinical studies and indicated the possibility of miRNA 
expression change in human liver (61). Overexpression of 
miRNA-122 is reported to increase the sensitivity of HCC 
cells to sorafenib (32). MiRNA-122 is also considered 
as a suppression of HCC tumor, which is resistance to 
doxorubicin (62). In this respect, a study showed that the 
enhanced expression of miR-122 in HepG2 cells, which are 
untreated by doxorubicin, could increase cellular sensitivity 
to chemotherapy drugs through down-regulation of MDR, 
ABCB1, and ABCF2 genes. Evaluation of cell cycle also 
indicated that the anti-proliferation effects of miRNA-122 
could be associated with cell cycle arrest in G0/G1 phase. 
Moreover, miRNA-122 treatment and doxorubicin could 
increase the number of HCC cells in G0/G1 phase. The 
results revealed that the increase of miRNA-122 expression 
could arrest the cell cycle and inhibit the cellular growth 
of HCC which could be accompanied by down-regulation 
of MDR-related genes (63). In another study, the role of 
miRNA-122 in HCC metabolism was analyzed and the 
results showed that PKM2 could have a significant role in 
aerobic glycolysis. The miRNA-122-PKM2 pathway could 
be introduced as a new method for treating HCC (62). In 
this regard, SFR could be assumed as a lower sensor of vascular 
endothelial growth factor essential for the angiogenesis of 
VEGF endothelial cells. It should be noted that miRNA-122 
can directly inhibit angiogenesis in vitro, and simultaneously 
inhibit ADAM10, SRF, and Igf1R genes (32).
Conclusions
Some of the miRNAs exclusive to HBV serum, such as 
miRNA-122, are likely to increase in the serum of HBV 
patients up to be 1.5-fold. Serum miR-122 levels can be 
highly correlated with HBsAg serum antigen indicating the 
quantity of HBV translation. Determining the correlated 
mechanism of HBsAg and miRNA-122 can be advantageous 
for understanding HBV viruses. In this respect, miRNA-122 
can differentiate between HBV carriers with high and low 
risks of disease progression. Apart from the potential role 
of miRNAs in diagnosing and classifying patients, they 
can be a good method for evaluating treatment responses. 
They can also act as a drug. Potentially, expression level 
of miRNA-122 can be a suitable biomarker for evaluating 
treatment results in HBV patients (Table 1). In fact, 
apart from diagnostic functions, miRNA-122 can be a 
treatment target considering that miRNA-122 can have 
a significant role in the proliferation of hepatitis viruses. 
Treatment effects of miRNA-122 in hepatocytes are also 
so efficient so that they can prevent hepatocarcinogenesis. 
Increased use of transcript me sequences can also present 
an impartial method for miRNAs recognition. Thus, 
more studies are needed to create a new evaluation system 
for different diseases or prognosis of HBV infections 
using miRNA. While miRNA is endowed with a high 
potential as a biomarker for HBV, further investigations 
should be conducted on optimum miRNAs or other 
diagnostic methods. The potential limitation of studies 
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can be the primary screening of the candidate miRNAs 
using microarray which typically contains only a limited 
set of probes that may not include recently-identified 
miRNAs nor adequately prevent cross-hybridization with 
unrepresented miRNAs. However, the tissue samples 
used in this study were small and inefficient, which were 
considered as a limitation. Accordingly, more research using 
multiple samples and functional tests were recommended 
to be carried out in order to confirm the validity of the 
given findings. Besides, experimental studies have indicated 
that miRNAs can have a significant role in the cell cycle 
of HBV, but more investigations should be conducted on 
miRNA-122 targeting the eradication of CCCDNA and 
viruses. The final objective should be creating a new HBV 
treatment method. According to the limited strategies used 
for preventing hepatic disease, HCC treatment, relationship 
between expression reduction of miRNA-122 and hepatic 
inflammation, fibrosis, steatosis (fatty change), and HCC; 
mimic miRNA-12 can be recognized as a functional method 
to reduce hepatic disease progression and improve HCC 
treatments. The future clinical trials using miRNA base 
molecules can thus present a bright perspective regarding 
hepatic disease treatment and HCC. Due to the all-
encompassing role of miRNAs in hepatic homeostasis, 
cholesterol biosynthesis, and fatty acid metabolisms; a vast 
range of studies is also necessary for identifying an efficient 
dose of miRNAs in treatments. An additional preclinical 
investigation will be also required to conclude the optimal 
level of miRNA mimics in therapies and to evaluate the 
potential risks related to miRNA-122 overexpression 
or reduction. Modulating miRNAs in disease states, 
especially cancer, can also represent a promising frontier 
for pharmacotherapy that may be used in conjunction 
with classical chemotherapy to control the consequences 
of deregulated miRNA levels within cells. MiRNA-122 
treatment can be advantageous in treating HBV/
Leishmania patients, negative and positive HCC patients, 
and also prevent nonalcoholic steatohepatitis (NASH) 
Table 1 Detailed characteristics of the related studies
Type Number of patients Findings Source
HBV-related 
HCC
40 HBV-related HCC 
patients
MiR-122 were down-regulated in HBV-related HCC patients and they were related 
to tumor size, lymph node metastasis, NM stage, anthological type, differentiation 
grade, liver cirrhosis, AFP, as well as HBV DNA
(64)
120 patients High plasma miRNA-122 expression was associated with poor overall survival (OS) 
in patients with HBV-related HCC that had undergone RFA
(65)
CHB 102 patients Circulating miRNA-122 significantly increased in the early stage of CHBLF patients (66)
198 patients Results suggested that serum micro-RNA levels were significantly associated with 
multiple aspects of HBV infection
(24)
89 patients Serum miR-122 levels were strongly correlated with HBs antigen (13)
HCC 40 patients HBV-human chimeric transcript HBx-LINE1 could serve as a molecular sponge for 
miRNA-122 and these findings illustrated a novel mechanism by which HBV could 
modulate hepatic cell functions
(53)
101 HCC patients MiRNA-122 was presented at higher levels in serum of patients with HCC 
compared with healthy individuals, suggesting miR-122 known to be liver-specific, 
was might serve as potential markers of cancer
(67)
HBV/HCV 76 patients Expression of serum miRNA-122 was increased in patients with hepatitis activity 
and it was reported to be at the highest levels in patients with HBV infection
(68)
HCC-derived 
cell line Huh7
In vitro MiRNA-122 could down-regulate SOCS3 and inhibit HBV replication by modulating 
the expression of type-I IFN
(69)
CHB, HCC 1,300 HBV-positive HCC 
cases, 1,344 HBV carriers, 
and 1,344 individuals with 
HBV clearance
Change of rs4309483 was likely to alter the expression of miRNA-122; thus, it 
could provide a protective effect from CHB but an increased risk for HCC in HBV 
carriers
(59)
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; HCV, hepatitis C virus.
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and cirrhosis. However, there are a lot of challenges along 
the way of developing an efficient system for miRNA-122 
mimic delivery to the body when they are supposed to be 
used in clinics. Moreover, optimizing the delivery path of 
miRNA, such as intra-portal or trans-arterial, is essential 
for successful miRNA-122 treatments of HCC patients. 
Developing new technologies for quantitative measurement 
of miRNA-122 in hepatic damages is also considered to 
be a major progress in diagnosis and prognosis of multiple 
hepatic diseases.
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